Feed ADXN
AD

Addex Therapeutics Ltd

ADXN · NASDAQ

$3.65 -5.44% (-$0.21)
1M -6.89%
Market Cap CHF 3.73M
P/E Ratio -
Div. Yield -
ROE 131.30%
Analiza

AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.

Piotroski F-Score Weak
1/9
Valuation
50 /100
Fair
P/S 50.39x
P/B 1.14x
P/E N/A
Growth
4 /100
Declining
Rev. growth 72.38%
Book val. growth 1.00%
EPS growth N/A
Profitability
0 /100
Weak
Gross margin 265.47%
Net margin 9,410.20%
FCF margin 3,143.37%
Quality
0 /100
Poor
ROIC 74.38%
ROE 131.30%
Asset turnover 0.02x
Debt
54 /100
Moderate
Debt/Equity 0.03x
Current ratio 0.97x
Int. coverage -1,432.34x
Stability
1 /100
Unstable
Beta 1.96x
Rev. volatility 56.78%
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o ADXN
Online

O podjetju

Addex Therapeutics Ltd (ADXN) is a Swiss biotechnology company focused on developing innovative drugs for the treatment of neurological and psychiatric disorders. The company leverages advanced technologies targeting allosteric modulation of receptors, enabling it to develop new therapeutic approaches for various conditions such as Parkinson's disease, schizophrenia, and other neurological disorders. Addex Therapeutics is known for its scientific expertise and strong focus on research and development. Addex Therapeutics Ltd (ADXN) shares could be suitable for investors looking for investments in the biotechnology and pharmaceutical research sector with an emphasis on innovative treatment methods.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Timothy Mark Dyer

Employees

3

Headquarters

Geneva

Prihajajoči dogodki

09 NOV.

Earnings

Upcoming earnings report

42d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.